Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 9)*
|
Aspire Biopharma Holdings, Inc. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
738920305 (CUSIP Number) |
08/04/2026 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 738920305 |
| 1 | Names of Reporting Persons
Lance Friedman | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
107,323.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
7.92 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: Includes 107,323 shares of common stock shares with a floor price of $7.92 per share. The Reporting Person also has Preferred Stock convertible into common stock with which contain a blocker prohibiting their conversion if it would result in the holder owning more than 9.99% of the outstanding common stock.
SCHEDULE 13G
|
| Item 1. | |
| (a) | Name of issuer:
Aspire Biopharma Holdings, Inc. |
| (b) | Address of issuer's principal executive offices:
194 Candelaro Drive, #233, Humacao, Puerto Rico, 00791 |
| Item 2. | |
| (a) | Name of person filing:
Lance Friedman |
| (b) | Address or principal business office or, if none, residence:
25 N Market Street, Suite 205, Jacksonville, Florida 32202 |
| (c) | Citizenship:
United States |
| (d) | Title of class of securities:
Common Stock |
| (e) | CUSIP No.:
|
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
|
| (b) |
Percent of class:
7.92 %
|
| (c) | Number of shares as to which the person has:
|
| (i) Sole power to vote or to direct the vote:
107,323 | |
| (ii) Shared power to vote or to direct the vote:
N/A | |
| (iii) Sole power to dispose or to direct the disposition of:
107,323 | |
| (iv) Shared power to dispose or to direct the disposition of:
N/A | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
Not Applicable
| |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable
| |
| Item 8. | Identification and Classification of Members of the Group. |
Not Applicable
| |
| Item 9. | Notice of Dissolution of Group. |
Not Applicable
|
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|